INVESTORS & MEDIA

INVESTORS & MEDIA

NEWS & EVENT

  • Home
  • INVESTORS & MEDIA
  • NEWS & EVENT

NEWS & EVENT 

Total 12 - 1 page
Subject
신주발행공고
익명 437 2026.03.12
신주발행공고
익명 977 2025.12.29
iLeadBMS Presents Preclinical Data on Novel Drug Candidate for Heart Failure at AFDD
익명 2,138 2024.11.21
iLeadBMS Presents Preclinical Data on IL21120033 for Heart Failure at ACC 2025
익명 2,181 2025.03.31
iLeadBMS Presents Preclinical Data on IL21120033, a First-in-Class ACKR3 Ago-PAM at EULAR 2025
익명 2,375 2025.06.14
iLeadBMS Announces Orphan Drug Designation Granted by the FDA for IL21120033 (CXCR7 Agonist) for Idiopathic Pulmonary Fibrosis
익명 2,451 2025.02.13
iLeadBMS Announces Positive Liver Fibrosis Results of IL1512 (CXCR7 Agonist) at the EASL 2024
익명 2,506 2024.07.10
iLeadBMS Announces Positive Preclinical Results of IL1512 (CXCR7 Agonist) at the ATS 2024
익명 2,625 2024.05.21
Ildong Pharmaceutical Group’s ‘iLeadBMS’ Presents Non-Clinical Results of its Novel NASH Drug Candidate at the AASLD
익명 2,715 2022.11.09
iLeadBMS’ Cyclin-K Molecular Glue Receives ODD from FDA for Gastric Cancer
익명 3,073 2024.10.07
iLeadBMS Announces Results of TPD Molecular Glue Research of IL2106 (CDK12 Molecular Glue and Cyclin-K degrader) at ESMO TAT 2024
익명 3,624 2024.02.27
Ildong Pharmaceutical Invests KRW 13,000,000,000 in iLeadBMS to Strengthen the Ecosystem of Novel Drug R&D
익명 5,597 2021.07.15
Address : 614, Dongtangiheung-ro, Hwaseong-si, Gyeonggi-do, Republic of Korea
E-mail : contact@ileadbms.com | T. 031-372-9950 | F. 070-4126-9951
Linkedin : https://www.linkedin.com/company/104793817

Copyright © Ileadbms. All Rights Reserved. Mobile